Transactions
1
Insider / ALNYLAM PHARMACEUTICALS, INC.
Cravatt Benjamin
Director at ALNYLAM PHARMACEUTICALS, INC.
Cravatt Benjamin, Director at ALNYLAM PHARMACEUTICALS, INC., has disclosed 1 transaction in ALNY since June 3, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed June 3, 2026, 2 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Cravatt Benjamin reported 1 transaction that was neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 1 | 4,393 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | Other A | June 1, 2026 | June 3, 2026 | 2d | 4,393 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 3, 2026 | Form 4 | 0001178670-26-000047 | 1 | published | EDGAR ↗ |
Other insiders at ALNYLAM PHARMACEUTICALS, INC.
- PYOTT DAVID E I Director 9 rows
- BRANDICOURT OLIVIER Director 6 rows
- SCHULMAN AMY W Director 3 rows
- HAMBURG MARGARET A Director 2 rows
- KELLOGG PETER N Director 2 rows
- Reitan Colleen F Director 2 rows
- Sigal Charles Elliott Director 2 rows
- Greenstreet Yvonne Chief Executive Officer 1 row
- SUPRAN BRYAN EVP, CLO and Secretary 1 row
Everyone on file, with contracts and lobbying under the company's name: ALNYLAM PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 1 | June 3, 2026 | June 3, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.